COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up researchReview Published on 2022-07-012023-07-08 Journal: Blood reviews [Category] COVID19(2023년), [키워드] breakthrough infections COVID-19 health outcomes hematologic malignancies SARS-CoV-2 Vaccine [DOI] 10.1016/j.blre.2022.100931 PMC 바로가기 [Article Type] Review
Neutralizing antibody activity against the B.1.617.2 (delta) variant 8 months after two-dose vaccination with BNT162b2 in health care workers의료 종사자를 대상으로 BNT162b2 2회 접종 후 8개월 후 B.1.617.2(델타) 변이체에 대한 중화 항체 활성Observational Study Published on 2022-07-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition antibody B.1.617.2 BNT162b2 Breakthrough infection breakthrough infections collected coronavirus COVID-19 cross-neutralization Delta delta variant detectable determined by different time point domain Epitopes FIVE Follow-up Health care Health care worker healthy individuals Humoral immunity IgG Immune escape Immunity in healthy individuals increasingly individual interquartile interquartile range Live virus longitudinal Longitudinal data neutralization Neutralizing Neutralizing activity neutralizing antibody observational study participant respiratory responsible SARS-CoV-2 significantly Transmissibility vaccination Vaccination strategies vaccine dose variant variants variants of concern were measured wild-type [DOI] 10.1016/j.cmi.2022.01.011 PMC 바로가기 [Article Type] Observational Study
Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic reviewSARS-CoV-2 mRNA 백신 접종 후 6개월 후 체액성 면역 반응의 현저한 감소 특성: 체계적인 검토Review Published on 2022-07-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration age anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anti-Spike IgG antibody Antibody Response Antibody titer Antibody titers appearance article binding domain BNT161b2 BNT162b2 booster Breakthrough infection breakthrough infections calculated characterization Comorbidities coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 mRNA Vaccination determine Effect Efficacy Evidence exhibited Factor finding highlight humoral humoral immune response Humoral immunity Humoral response IgG Immunoglobulin Immunoglobulin G independent independent of Kinetics Longitudinal data Messenger RNA Moderna mRNA mRNA 1273 mRNA BNT162b2 mRNA vaccination mRNA-1273 Participants peak levels Pfizer-BioNTech postvaccination presence of comorbidities reached reported respiratory second dose serostatus Serum level serum levels severe acute respiratory syndrome Coronavirus Sex systematic review Vaccination strategy Vaccine Vaccines variant waning immunity was performed [DOI] 10.1002/jmv.27688 PMC 바로가기 [Article Type] Review
Omicron infection enhances Delta antibody immunity in vaccinated personsOmicron 감염은 예방 접종을 받은 사람의 Delta 항체 면역을 향상시킵니다.Article Published on 2022-07-012022-09-11 Journal: Nature [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] absolute levels acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody immunity B.1.617.2 Beta BNT162b2 breakthrough infections coronavirus cross-protection Delta develop dominant elicit ENhance enrolment focus Follow-up follow-up time geometric geometric mean Immunity individual Infection interquartile range Johnson & Johnson median moderate neutralization neutralization capacity neutralization test neutralizing immunity offer omicron other variants participant Participants Pfizer Protective reduction respiratory severe acute respiratory syndrome Coronavirus South Africa Symptom symptom onset titre vaccinated individual vaccinated individuals vaccination variant variants virus Virus neutralization viruses [DOI] 10.1038/s41586-022-04830-x PMC 바로가기 [Article Type] Article
Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failureShort communication Published on 2022-07-012022-10-05 Journal: Vaccine [Category] COVID19(2023년), SARS, 바이오마커, 임상, [키워드] age Aged breakthrough infections Characteristics clinical Clinical characteristics Comorbidity COVID COVID-19 COVID-19 breakthrough infections COVID-19 vaccine COVID-19 vaccines death described Elderly patient first positive Hospitalization Hospitalized immunization IMPROVE low-flow oxygen therapy male Mortality Older Older age outcome overall mortality Patient Prognosis SARS-CoV-2 PCR significantly specific treatment treatment with tocilizumab vaccination Vaccine with COVID-19 [DOI] 10.1016/j.vaccine.2022.06.003 [Article Type] Short communication
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic임상 실습의 최근 발전: COVID-19 대유행 중 염증성 장 질환 관리Review Published on 2022-07-012022-09-11 Journal: Gut [Category] COVID19(2023년), SARS, 치료기술, [키워드] acquisition adverse outcome adverse outcomes antibody booster dose bowel Breakthrough infection breakthrough infections Cancer cancers Corticosteroid Corticosteroids COVID-19 COVID-19 in patient COVID-19 pandemic Crohn's disease de novo decrease develop diagnoses disease course dose Evidence Future General population Guidance hospitalisation hospitalisations Humoral response humoral responses IBD immune immune response immunosuppressive therapies immunosuppressive therapy increased risk Inflammatory Inflammatory bowel disease management medication medications Necrosis outcome outcomes pandemic Patient patients potential risk primary dose raised receive recent remained Research risk risk of COVID-19 SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines TNF treated Treatment ulcerative ulcerative colitis Vaccine vaccine response Vaccines [DOI] 10.1136/gutjnl-2021-326784 PMC 바로가기 [Article Type] Review
Effect of vaccination on household transmission of SARS-CoV-2 Delta variant of concern우려되는 SARS-CoV-2 Delta 변이체의 가정 전염에 대한 예방접종의 효과Article Published on 2022-06-302022-09-11 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, [키워드] Breakthrough infection breakthrough infections concern Contact Delta delta variant Effect Effective vaccines Effectiveness exhibited household contacts household transmission individual Infection infectiousness National PROTECT public health reduce reducing SARS-CoV-2 SARS-COV-2 infection secondary case seeking susceptibility susceptibility to infection the vaccine transmission of SARS-CoV-2 vaccination Vaccinations Vaccine Viral load [DOI] 10.1038/s41467-022-31494-y PMC 바로가기 [Article Type] Article
Follow up of the Humoral Response in Healthcare Workers after the Administration of Two Dose of the Anti SARS-CoV-2 Vaccines-Effectiveness in Delta Variant Breakthrough Infections항 SARS-CoV-2 백신 2회 투여 후 의료 종사자의 체액 반응 추적 - 델타 변이형 돌발 감염에서의 효과Article Published on 2022-06-242022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] anti-S antibody breakthrough infections circulation correlation Coverage Delta delta variant demonstrated doses elicit FIVE HCW HCWs healthcare worker Healthcare workers humoral Humoral response idea IgG IgG antibody implementation infected patient infected patients Infection infections management marker median mRNA vaccine mRNA vaccines new infections no infection other variant other variants pandemic participant Participants Patient PCR positive performed positive positive result predict response SARS-CoV-2 SARS-CoV-2 IgG antibody serological serology Significant significant differences Spain subsequent summer Support the SARS-CoV-2 These data vaccination Vaccine worker [DOI] 10.3390/v14071385 PMC 바로가기 [Article Type] Article
A Newly Engineered A549 Cell Line Expressing ACE2 and TMPRSS2 Is Highly Permissive to SARS-CoV-2, Including the Delta and Omicron VariantsACE2 및 TMPRSS2를 발현하는 새로 설계된 A549 세포주는 Delta 및 Omicron 변이체를 포함하여 SARS-CoV-2에 매우 관대합니다.Article Published on 2022-06-232022-09-11 Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료제, [키워드] A549 A549 cell A549 cells ACE2 ACE2 receptor acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 alveolar angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 anti-SARS-CoV-2 Antiviral antiviral drug antiviral drugs antivirals breakthrough infections can be used Cell coronavirus Critical Culture Delta delta and omicron variants drugs EIDD-1931 Express expressed expressing Factor Host human ACE2 human cell identify Including Infection infection with SARS-CoV-2 inhibit SARS-CoV-2 lack LINE nelfinavir New Nirmatrelvir omicron Omicron variants Permissive Remdesivir respiratory Respiratory virus infections SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants Serine severe acute respiratory syndrome Coronavirus Spike protein susceptible the SARS-CoV-2 TMPRSS2 transcript transducing transmembrane serine protease transmembrane serine protease 2 variant Viral viral entry virus infections [DOI] 10.3390/v14071369 PMC 바로가기 [Article Type] Article
Host chitinase 3-like-1 is a universal therapeutic target for SARS-CoV-2 viral variants in COVID-19숙주 키티나제 3-유사-1은 COVID-19의 SARS-CoV-2 바이러스 변이체에 대한 보편적인 치료 표적입니다Article Published on 2022-06-232022-09-11 Journal: eLife [Category] COVID19(2023년), SARS, 변종, [키워드] accumulate ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Alpha anti-CHI3L1 antibody Antibody neutralization Beta breakthrough infections caused Cell CHI3L1 chitinase Concentration coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 defined Delta delta variant demonstrated determine effective inhibitor epithelial epithelial cell Express FRG genetic variability host tissue induce Infection Infectious disease inhibit inhibitor Intervention kasugamycin Laboratory lethal disease Microbiology morbidity and mortality neutralization omicron priming protease pseudovirus pseudoviruses S protein SARS-CoV-2 viral Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe disease spike stimulate strain susceptibility the disease therapeutic target Therapeutics Transmissibility variant variants variants of concern viral variant viruses VoC Waves worldwide pandemic [DOI] 10.7554/eLife.78273 PMC 바로가기 [Article Type] Article